← Back to all trials
Recruiting
NCT05653323
A Phase 1 Dose Escalation Study of VX-993 in Healthy Participants
Conditions: Pain
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: 1
Phase: PHASE1
Enrollment: 90
Sponsor: Vertex Pharmaceuticals Incorporated
Location: United Kingdom
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VX-993 at different doses in healthy participants.
Eligibility Criteria
Key Inclusion Criteria:Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m^2)A total body weight of more than (>) 50 kgParticipants of non-childbearing potentialNonsmoker or ex-smoker for at least 3 months before screeningKey Exclusion Criteria:History of febrile illness or other acute illness within 14 days before the first dose of study drugAny condition possibly affecting drug absorptionOther protocol defined Inclusion/Exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT05653323). StuddyBuddy aggregates publicly available trial information.
